Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — H1 FY2017 Earnings Presentation
16 slides from Dr. Lal Pathlabs's earnings presentation, Nov 3, 2016
Slide 1: Dr. Lal PathLabs Limited (LPL) Q2 & H1 FY17 Results Presentation
Dr. Lal PathLabs Limited (LPL) Q2 & H1 FY17 Results Presentation November 03, 2016
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q2 & H1 FY2017 Financial Performance 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places.
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 172 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,559 Patient Service diagnostic services Centers (PSCs) and 4,967 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralized IT panels
Slide 4: Key Highlights
Key Highlights Performance gains driven by growth in volumes, seasonal factors, higher realization per patient, upward price revision and improved operational leverage During Q2 FY17 LPL : Revenues grew 21.5% at Rs. 2,621.7 mn from Rs. 2,157.3 mn. Price revision contributed 2.6% to revenue g
Slide 5: Q2 FY17 Financial Performance
Q2 FY17 Financial Performance Particulars (Rs. mn) Q2 FY17 Q2 FY16 Growth % H1 FY17 H1 FY16 Growth % Revenues 2,621.7 2,157.3 21.5% 4,850.1 4,050.4 19.7% Total Expenditure 1,823.5 1,794.1 1.6% 3,447.9 3,195.1 7.9% ESOP - 216.6 - - 239.1 - EBITDA (excl ESOP) 798.2 579.8 37.7% 1,402.2 1,094.4 28.1% Ma
Slide 6: Financial Highlights
Financial Highlights Revenues All figures in Rs mn 2,622 2,157 2,228 1,893 1,886 1,977 Q1FY16 Q2FY16 Q3FY16 Q4FY16 Q1FY17 Q2FY17 Q2 FY17 revenues increased 22% on the basis of improved volumes and benefit of better realizations; 13.6% higher sample volumes in Q2 was the result of: 2,622 4,850 o
Slide 7: Financial Highlights
Financial Highlights All figures in Rs mn EBITDA (excl ESOP) 1,402 798 1,094 580 Q2FY16 Q2FY17 H1 FY16 H1 FY17 EBITDA (excl ESOP) stood 38% higher with corresponding EBITDA Margins at 30.4% during Q2 FY17 This EBITDA growth was favourably impacted by seasonal fevers, price increase and operating
Slide 8: Financial Highlights
Financial Highlights All figures in Rs mn PBT (excl ESOP + Excp Item) 794 1,393 558 1,049 Q2FY16 Q2FY17 H1 FY16 H1 FY17 PBT (excl ESOP + Excp Item) growth during Q2 FY17 stood at 42% Margins were at 25.9% PAT during Q2 FY17 is not comparable on YoY basis due to ESOP charge taken in Q2 FY16 8
Slide 9: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,559 172 5,668 164 1,340 4,967 4,225 1,064 146 824 2,879 131 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 No. of patients (mn) No. of samples (mn) 26.3 12.0 21.7 19.0 9.9 16.0 15.5 9.0 7.7 7.0 FY13 FY14 FY15 FY
Slide 10: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “We delivered solid second quarter financial results driven by our passion to be pioneers in the diagnostic space and provide the highest quality of services to our patients. Thus our
Slide 11: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services . Initiatives to improve brand c
Slide 12: Corporate Overview
Corporate Overview • LPL Strategy for future growth • Experienced Management team 12
Slide 13: LPL Strategy for future growth
LPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 13
Slide 14: LPL Strategy for future growth
LPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Life
Slide 15: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Manoj Garg Shankha Banerjee Chief Financial Officer Chief Human Resources Officer COO – Strategic
Slide 16: Contact us
Contact us About Dr Lal PathLabs Limited (LPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and